Cartesian Therapeutics Inc (NASDAQ:RNAC) price on Thursday, July 03, fall -1.41% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $11.21.
A look at the stock’s price movement, the close in the last trading session was $11.37, moving within a range at $10.985 and $11.525. Turning to its 52-week performance, $26.50 and $8.46 were the 52-week high and 52-week low respectively. Overall, RNAC moved 13.23% over the past month.
Cartesian Therapeutics Inc’s market cap currently stands at around $290.95 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-08.
The average forecast suggests down to a -97.69% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 3.48M, representing a -91.07% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RNAC is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
RNAC’s current price about 6.82% and 6.50% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.38, while 7-day volatility ratio is 8.70% and 7.94% in the 30-day chart. Further, Cartesian Therapeutics Inc (RNAC) has a beta value of 0.41. Analysts have given the company’s stock an average 52-week price target of $43, forecast between a low of $40 and high of $45. Looking at the price targets, the low is -256.82% off current price level while to achieve the yearly target high, price needs to move -301.43%. Nonetheless, investors will most likely welcome a -283.59% jump to $43 which is the analysts’ median price.
If we refocus on Cartesian Therapeutics Inc (NASDAQ:RNAC), historical trading data shows that trading volumes averaged 82660.0 over the past 10 days and 89.08K over the past 3 months. The company’s latest data on shares outstanding shows there are 25.94 million shares.
The 67.98% of Cartesian Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 20.21% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.63 million on 2025-06-13, giving us a short ratio of 39.45. The data shows that as of 2025-06-13 short interest in Cartesian Therapeutics Inc (RNAC) stood at 2551.0 of shares outstanding, with shares short rising to 2.51 million registered in 2025-05-15. Current price change has pushed the stock -53.81% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RNAC stock continues to rise going into the next quarter.
